Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0151 | 0 | 0.5 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0305 | 1 | 1 |
Leishmania major | p450 reductase, putative | 0.0305 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0305 | 1 | 0.5 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0305 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0305 | 1 | 0.5 |
Chlamydia trachomatis | sulfite reductase | 0.0188 | 0.2407 | 0.5 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0305 | 1 | 1 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0305 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0305 | 1 | 1 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0305 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0305 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0305 | 1 | 0.5 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0305 | 1 | 0.5 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0305 | 1 | 0.5 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0305 | 1 | 1 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0305 | 1 | 0.5 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0154 | 0.0151 | 0.0151 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0305 | 1 | 0.5 |
Trypanosoma cruzi | p450 reductase, putative | 0.0305 | 1 | 0.5 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.027 | 0.7743 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0305 | 1 | 0.5 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0188 | 0.2407 | 0.2407 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0305 | 1 | 0.5 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0305 | 1 | 1 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0305 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0151 | 0 | 0.5 |
Brugia malayi | FAD binding domain containing protein | 0.0305 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.027 | 0.7743 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 8.3 uM | Tested in vitro for anti-leishmanial activity against Leishmania donovani | ChEMBL. | 9822551 |
IC50 (functional) | = 8.3 uM | Tested in vitro for anti-leishmanial activity against Leishmania donovani | ChEMBL. | 9822551 |
IC50 (functional) | = 8.7 uM | Inhibitory activity against phytohemmagglutinin A-induced proliferation of human lymphocytes | ChEMBL. | 9822551 |
Inhibition (binding) | Inhibition of Staphylococcus aureus SA-1199B NorA expressed in Escherichia coli DH10B assessed as inhibition of Hoechst 33342 dye efflux at 2 ug/ml after 150 to 160 secs by spectrofluorometric analysis in presence of 50 uM Mg2+ | ChEMBL. | 22682300 | |
Inhibition (functional) | Inhibition of Hoechst 33342 dye in norA-deficient Escherichia coli DH10B expressing pTrc99A at 2 ug/mL by spectrofluorometer analysis | ChEMBL. | 22682300 | |
Inhibition (binding) | Inhibition of Staphylococcus aureus SA-1199B NorA expressed in Escherichia coli DH10B assessed as inhibition of Hoechst 33342 dye efflux by spectrofluorometric analysis in presence of 50 uM Mg2+ | ChEMBL. | 22682300 | |
Inhibition (binding) | Inhibition of Staphylococcus aureus SA-1199B NorA expressed in Escherichia coli DH10B assessed as inhibition of Hoechst 33342 dye efflux at 2 ug/ml by spectrofluorometric analysis in presence of 50 uM Mg2+ | ChEMBL. | 22682300 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Leishmania donovani | ChEMBL23 | 9822551 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.